SBC Medical Group Holdings
Closed (deSPAC)Health Care · medical services organization (MSO) for clinics
- What it is
- A private company in health care preparing to list via a SPAC merger. Full profile in progress.
- What it’s doing now
- Merging with Pono Capital Two, Inc. (PTWO) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
What the company says about itself
Web research — not audited[WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction values SBC at $1.2 billion" [https://www.nasdaq.com/press-release/sbc-medical-group-holdings-incorporated-a-medical-services-healthcare-company] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "the transaction will close in the fourth quarter of 2023" [https://www.nasdaq.com/press-release/sbc-medical-group-holdings-incorporated-a-medical-services-healthcare-company] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Expected Close: “Fourth Quarter of 2023” or “First Quarter of 2024”" [https://www.carnegieparkcapital.com/2022/10/03/pono-capital-two-inc-ptwo-merge-with-sbc-medical-group-holdings-private/]
Source: company web presence · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
SBC Medical Group Holdings is merging with Pono Capital Two, Inc. (PTWO) currently marked Closed (deSPAC).
| Headline equity value | — |
How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is SBC Medical Group Holdings going public?
SBC Medical Group Holdings has an approved merger with the SPAC Pono Capital Two, Inc. (PTWO). Deal status: Closed (deSPAC).
Does SBC Medical Group Holdings have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC